《SOFTMEDX-NEW:2024INTERIMREPORT.pdf》由会员分享,可在线阅读,更多相关《SOFTMEDX-NEW:2024INTERIMREPORT.pdf(11页珍藏版)》请在三个皮匠报告上搜索。
1、 0 SoftMedx Healthcare Limited 4 4 InterimInterim Interim Report 2024 1 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Director LIN Pinzhuo Independent Non-executive Directors NGOK Ho Wai TANG Cuihuen YIU Chun Wing AUDIT COMMITTEE YIU Chun Wing(Chairperson)NGOK Ho Wai TANG Cuihuen NOMINATION COM
2、MITTEE NGOK Ho Wai(Chairperson)LIN Pinzhuo YIU Chun Wing REMUNERATION COMMITTEE YIU Chun Wing(Chairperson)LIN Pinzhuo NGOK Ho Wai RISK MANAGEMENT COMMITTEE YIU Chun Wing(Chairperson)LIN Pinzhuo NGOK Ho Wai COMPANY SECRETARY LAM Sung Him,Gaston STOCK CODE 648 REGISTERED OFFICE Level 38,Infinitus Plaz
3、a 199 Des Voeux Road Central Hong Kong SHARE REGISTRAR Tricor Tengis Limited 17/F,Far East Finance Centre 16 Harcourt Road Hong Kong PRINCIPAL BANKERS Bank of China(Hong Kong)Limited The Hong Kong and Shanghai Bank Corporation Limited INDEPENDENT AUDITORS CL Partners CPA Limited Certified Public Acc
4、ountants Registered Public Interest Entity Auditor COMPANY WEBSITE .hk 2 SoftMedx Healthcare Limited MANAGEMENT DISCUSSION AND ANALYSIS REVIEW OF FINANCIAL RESULTS SoftMedx Healthcare Limited(the“Company”,together with its subsidiaries,the“Group”)is engaged in medical and well-being business for dis
5、tribution of medical equipment and products involving dental equipment and products.The Group recorded revenue of HK$30.7 million for the six months ended 30 June 2024(2023:HK$20.6 million)with gross profit of HK$10.8 million(2023:HK$11.4 million)at gross profit margin of 35.1%(2023:55.3%).The conso
6、lidated loss and consolidated loss attributable to the owners of the Company amounted to HK$6.1 million(2023:HK$3.4 million)and HK$6.1 million(2023:HK$3.9 million)respectively.The increase in loss was mainly attributable to the loss arising from the change in fair value of financial assets at fair v